阜阳荨麻疹好点的医院阜阳哪个医院有皮肤,阜阳轻度扁平疣医院,阜阳哪家阜阳湿疹医院,阜阳痘痘医院哪个,阜阳可以有效祛除豆印的医院是那家,阜阳看跖尤哪个医院好,阜阳哪里有治皮肤病的好医院

BEIJING, July 3 (Xinhuanet) -- The Atlantis mission to be launched by NASA on July 8 will not be an end to the space age, as some media suggest.Although it is the final mission of the space shuttle, it will open up "the next chapter" in the United States' space exploration, NASA's administrator Charles Bolden Jr said at the National Press Club in Washington on Friday."When I hear people say - or listen to media reports - that the final shuttle flight marks the end of US human space flight, I have to say . . . these folks must be living on another planet," he said."As a former astronaut and the current NASA administrator, I'm here to tell you that American leadership in space will continue for at least the next half-century because we have laid the foundation for success - and for NASA, failure is not an option," he said.NASA administrator Charles Bolden Jr drew a lot of media attention during his speech at the National Press Club in Washington DC.One of the foundations is the "unprecedented" research capabilities the International Space Station (ISS) now possesses, largely thanks to the space shuttle missions.Although some media imply that "the game will be up" once the ISS is out of orbit in 2020, he said the splendid research results and rich knowledge astronauts and scientists have accumulated through more than 1,200 experiments since 1998 have laid out "a stepping-stone to the rest of the solar system and the tip of what comes next".As NASA turns a new page, it will "focus on deep space exploration", while leaving US private companies to operate low Earth orbit transportation systems for tourism and business, he said.NASA will develop "a deep space crew vehicle and an evolvable heavy-lift rocket," he said. The moon, asteroids and Mars will be the next destinations for humans to live and work, he said."We will maintain and grow US leadership in space and derive all the benefits that flow from it. Tomorrow's space program is taking shape right now," he said.

WELLINGTON, July 26 (Xinhua) -- Children born early are less likely to develop serious behavioral problems than previously thought because previous studies may have relied too much on the opinions of "sensitive" parents, according to a controversial New Zealand research.The study by the Child Development Research Group at the University of Canterbury looked at the emotional and behavioral adjustment of children born very preterm (VPT).It showed that by age 6 children born very preterm (less than 33 weeks) were at an increased risk of emotional and attentional problems when compared with their full term peers, said a statement from the university.However, the findings suggested the risks may be lower than previous studies had suggested, because previous studies primarily relied on parents to provide information on their children's conditions, said lead author Samudragupta Bora."While parents are an important source of information about their child, it is also important to gather information from other significant people in the child's life such as their classroom teacher," said Bora.Bora and other members of the research team, found that parents reported higher rates of emotional and attention problems in their children than teachers did."Having a baby born prematurely is an extremely stressful experience for parents. During their baby's stay in the neonatal unit most parents will have been alerted to the possibility of their child developing problems such as behavioral difficulties in the future due to being born too early. Therefore, very understandably, many parents of these children are very sensitive to the possibility of developmental problems," he said."The use of multiple informants - parents, teachers and clinical observation - to assess VPT children's well-being is important to minimize the effects of report source bias and the over or under-identification of adjustment problems in children born VPT," said Bora."This is controversial because it shows that reliance on parents or teachers alone can lead to data validity issues."Although children born VPT were at higher risk of showing emotional and attentional problems, the risks of more severe problems were relatively modest, said Bora.The findings have been published the Journal of Paediatrics and Child Health.

BUJUMBURA, May 31(Xinhua) -- As the World No Tobacco Day is celebrated on Tuesday, many Burundians feel happy that they have given up smoking thanks to herbal drugs.Evariste Ndikumwami, 55, residing in the Burundian capital Bujumbura, said he had been smoking for 30 years, but gave up smoking in January after taking herbal drugs prescribed by an abbot."I had been smoking since my teenage and I gave up smoking in January (this year) after I took herbal drugs that I got from a Roman Catholic priest from Uganda working at Rugari parish in the province of Muyinga, some 210 km northeast of the Burundian capital Bujumbura," Ndikumwami told Xinhua.Ndikumwami said he used to smoke a pack of 20 cigarettes per day, adding that he had found it hard to give up smoking.He said, "I took the herbal drugs for 15 days. The abbot prescribed me two herbal drugs -- one to be smoked for five days at daytime when I desire to smoke and another one to be applied around the nostrils at night."After the medication period, he never felt the desire for smoking cigarettes, he said."When my friends realized I was no longer smoking, they asked me which drugs I took to give up smoking. I directed them to the abbot who had healed me and they also got cured and stopped smoking," Ndikumwami said.

WASHINGTON, Aug. 16 (Xinhua) -- The White House announced Tuesday that the U.S. Departments of Agriculture, Energy and Navy will invest up to 510 million U.S. dollars in partnership with the private sector to facilitate the country's biofuel industry development."Biofuels are an important part of reducing America's dependence on foreign oil and creating jobs here at home," U.S. President Barack Obama said in a White House statement.The initiative is a response to a directive from Obama issued in March as part of the Blueprint for A Secure Energy Future, the administration's framework for reducing dependence on foreign oil."But supporting biofuels cannot be the role of government alone. That's why we're partnering with the private sector to speed development of next-generation biofuels that will help us continue to take steps towards energy independence and strengthen communities across our country," Obama added.The joint plan calls for the three departments to invest up to 510 million dollars in the next three years, which will require substantial cost share from private industry, in a bid to reduce U. S. reliance on foreign oil and create jobs at home."By building a national biofuels industry, we are creating construction jobs, refinery jobs and economic opportunity in rural communities throughout the country," said U.S. Agriculture Secretary Tom Vilsack.White House figures revealed that the world's largest economy spends more than 300 billion dollars on imported crude oil every year.With a slackening economic recovery and the government's approval rate at a record low level, the Obama administration is rolling out a string of measures in recent days to accelerate economic growth and job creation.

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.